文献速递胃肠动力与功能性疾病

健康受试者单次和多次口服替戈拉生与瑞伐拉生的药效学研究

Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects.
PubMed 文献 · Aliment Pharmacol Ther · 2020-11-01

在幽门螺杆菌阴性的健康韩国男性受试者中开展随机、开放标签、阳性对照研究,比较替戈拉生50 mg与瑞伐拉生200 mg每日一次口服7天后的24小时胃内pH监测和血清胃泌素。结果显示替戈拉生对胃酸的抑制作用强于瑞伐拉生,两者耐受性均良好。

要点

  • 单次给药后替戈拉生%Time pH≥4为54.5%,高于瑞伐拉生的25.1%。
  • 多次给药后替戈拉生%Time pH≥4为68.2%,高于瑞伐拉生的25.3%。
  • 夜间12小时%Time pH≥4替戈拉生为71.8%,高于瑞伐拉生的31.9%。

核心结论

  • 替戈拉生50 mg对胃酸的抑制作用强于瑞伐拉生200 mg,两者耐受性均良好。

研究设计与样本

  • 随机、开放标签、阳性对照研究,纳入幽门螺杆菌阴性的健康韩国男性受试者。
  • 替戈拉生50 mg或瑞伐拉生200 mg口服,每日一次,连续7天。
  • 通过24小时胃内pH监测和血清胃泌素进行药效学评价,并收集包括血清microRNA-122(miR-122)在内的安全性参数。

主要发现

  • 单次给药后,替戈拉生%Time pH≥4为54.5%,瑞伐拉生为25.1%,替戈拉生更高。
  • 多次给药后,替戈拉生%Time pH≥4为68.2%,瑞伐拉生为25.3%,替戈拉生更高。
  • 夜间12小时%Time pH≥4,替戈拉生为71.8%,瑞伐拉生为31.9%,替戈拉生更高。
  • 两种药物的血清胃泌素变化均无临床意义。
  • 尽管每种药物的血清miR-122均轻度升高,但结合包括AST和ALT水平在内的其他安全性参数,替戈拉生和瑞伐拉生均耐受性良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Potassium-competitive acid blockers (P-CABs) are emerging as novel treatments for acid-related disorders including gastroesophageal reflux disease. Tegoprazan and revaprazan are approved P-CABs in South Korea, but the pharmacodynamics and safety/tolerability of the two drugs have never been compared. AIMS: To evaluate the pharmacodynamics and safety/tolerability of tegoprazan and revaprazan after single and multiple oral doses METHODS: A randomised, open-label, active-controlled study was conducted in Helicobacter pylori-negative healthy Korean male subjects. Tegoprazan 50 mg or revaprazan 200 mg was administered orally, once daily for 7 days; 24-h intragastric pH monitoring and serum gastrin were measured for pharmacodynamic evaluation. Safety parameters including serum microRNA-122 (miR-122) level were also collected. RESULTS: After a single dose, the %Time pH ≥4 for tegoprazan was greater than that for revaprazan (54.5% vs 25.1%). After multiple doses, the %Time pH ≥4 for tegoprazan was also greater than that for revaprazan (68.2% vs 25.3%). %Time pH ≥4 during 12 hours at nighttime for tegoprazan was greater than that for revaprazan (71.8% vs 31.9%). The changes in the serum gastrin were not clinically significant for either drug. Despite the slight increases of serum miR-122 for each drug, tegoprazan and revaprazan were well tolerated considering other safety parameters including AST and ALT levels. CONCLUSION: Tegoprazan 50 mg showed stronger gastric acid suppression than revaorazan 200 mg. Both drugs were well tolerated.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sunwoo J, Ji SC, Oh J, et al. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects. Aliment Pharmacol Ther. 2020. PMID: 33131095. doi:10.1111/apt.16121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。